Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Brain ; 138(Pt 12): 3610-22, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26490328

RESUMO

Currently there is no neuroprotective or neurorestorative therapy for Parkinson's disease. Here we report that transient receptor potential vanilloid 1 (TRPV1) on astrocytes mediates endogenous production of ciliary neurotrophic factor (CNTF), which prevents the active degeneration of dopamine neurons and leads to behavioural recovery through CNTF receptor alpha (CNTFRα) on nigral dopamine neurons in both the MPP(+)-lesioned or adeno-associated virus α-synuclein rat models of Parkinson's disease. Western blot and immunohistochemical analysis of human post-mortem substantia nigra from Parkinson's disease suggests that this endogenous neuroprotective system (TRPV1 and CNTF on astrocytes, and CNTFRα on dopamine neurons) might have relevance to human Parkinson's disease. Our results suggest that activation of astrocytic TRPV1 activates endogenous neuroprotective machinery in vivo and that it is a novel therapeutic target for the treatment of Parkinson's disease.


Assuntos
Astrócitos/metabolismo , Fator Neurotrófico Ciliar/metabolismo , Neurônios Dopaminérgicos/metabolismo , Neuroproteção , Doença de Parkinson/metabolismo , Doença de Parkinson/patologia , Substância Negra/metabolismo , Animais , Subunidade alfa do Receptor do Fator Neutrófico Ciliar/metabolismo , Modelos Animais de Doenças , Neurônios Dopaminérgicos/patologia , Feminino , Humanos , Regeneração Nervosa , Doença de Parkinson/fisiopatologia , Ratos , Substância Negra/citologia , Substância Negra/patologia , Canais de Cátion TRPV/metabolismo
2.
Cell ; 144(5): 689-702, 2011 Mar 04.
Artigo em Inglês | MEDLINE | ID: mdl-21376232

RESUMO

A hallmark of Parkinson's disease (PD) is the preferential loss of substantia nigra dopamine neurons. Here, we identify a new parkin interacting substrate, PARIS (ZNF746), whose levels are regulated by the ubiquitin proteasome system via binding to and ubiquitination by the E3 ubiquitin ligase, parkin. PARIS is a KRAB and zinc finger protein that accumulates in models of parkin inactivation and in human PD brain. PARIS represses the expression of the transcriptional coactivator, PGC-1α and the PGC-1α target gene, NRF-1 by binding to insulin response sequences in the PGC-1α promoter. Conditional knockout of parkin in adult animals leads to progressive loss of dopamine (DA) neurons in a PARIS-dependent manner. Moreover, overexpression of PARIS leads to the selective loss of DA neurons in the substantia nigra, and this is reversed by either parkin or PGC-1α coexpression. The identification of PARIS provides a molecular mechanism for neurodegeneration due to parkin inactivation.


Assuntos
Doença de Parkinson/metabolismo , Proteínas Repressoras/metabolismo , Transativadores/metabolismo , Animais , Encéfalo/metabolismo , Encéfalo/patologia , Dopamina/metabolismo , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Fator 1 Relacionado a NF-E2/metabolismo , Doenças Neurodegenerativas/metabolismo , Neurônios/metabolismo , Fator 1 Nuclear Respiratório/metabolismo , Coativador 1-alfa do Receptor gama Ativado por Proliferador de Peroxissomo , Ratos , Fatores de Transcrição , Ubiquitina-Proteína Ligases/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...